Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Gynecologic Cancer

Gynecologic Cancer

11

Pipeline Programs↗

12

Active Trials↗

7

Companies Involved↗

Gynecologic Cancer is an emerging landscape with 11 programs across 7 companies. The most active players are Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Chongqing Precision Biotech Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

25/100

Mech. Concentration

50/100

Completion Rate

82/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

1 program

Chongqing Precision Biotech Co., Ltd

1 program

Pipeline

Programs by Phase

Preclinical4

Floseal Application

Asan Medical Center

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Standard Premedication

Seoul National University Hospital

Reduced Premedication

Seoul National University Hospital

Phase 12

CD70 CAR-T Cells

Chongqing Precision Biotech Co., Ltd

Gadobutrol

Bayer

Phase 25

Avutometinib

Memorial Sloan Kettering Cancer Center

Defactinib

Verastem, Inc.

SSGJ-707

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Paclitaxel

Teva

Carboplatin

Avyxa

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

91%

Small molecule

10 of 11 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

25

clinical trials

Completed9 · 36%

Recruiting9 · 36%

Not yet recruiting2 · 8%

Unknown status2 · 8%

Active, not recruiting1 · 4%

Withdrawn1 · 4%

Other1 · 4%

Clinical Trials

Trial Activity

25 trials

The Impact of Massage Therapy on Pain and Anxiety of Patients With Gynecologic Cancer While Receiving Infusion Treatment (IMPACT)

Recruiting·—·Preclinical·NCT07502157·24 enrolled

Phase II Clinical Trial of Cesium-131 Low-dose Rate Interstitial Brachytherapy as an Organ-preserving Irradiation Technique for Recurrent Cervical and Endometrial Cancer

Recruiting·—·Preclinical·NCT07631572·10 enrolled

Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05787561·40 enrolled

Implement and Evaluate the CARE Tool in a Randomized Trial

Recruiting·WWashington University School of Medicine·Preclinical·NCT07296887·430 enrolled

REGYNERA(Dia)TION: An Ambispective International Multicenter Patient Registry of Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Malignancies

Recruiting·AAffidea Nu-med Center of Oncological DIagnostics and Therapy·N/A·NCT07667192·500 enrolled

Evaluation of a Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment in an Underserved Gynecology Population

Recruiting·WWeill Medical College of Cornell University·Preclinical·NCT05562778·150 enrolled

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients

Recruiting·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·NCT06522828·80 enrolled

Novel Imaging Technique to Assess Gynecologic Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04893434·20 enrolled

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06215950·36 enrolled

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

Active, not recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT05677048·205 enrolled

Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies Using Full-Field Optical Coherence Tomography and Dynamic Cell Imaging: A Step From Image Guided Surgery Towards Deep Learning Applications

Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT07702721·160 enrolled

Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

Not yet recruiting·SSeoul National University Hospital·N/A·NCT06977594·1,000 enrolled

Examining the Impact of Culturally and Linguistically Diverse Backgrounds on Patient Care and Experiences in Women With Gynecologic Malignancies (iCALD-2): A Questionnaire Study

Completed·UUniversity Health Network, Toronto·N/A·NCT05971303·45 enrolled

The Effect of Guided Imagery on Nausea, Vomiting, Retching, Anxiety and Quality of Life in Gynecologic Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial

Completed·BBaskent University·Preclinical·NCT07408349·49 enrolled

Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

Completed·National Cancer Institute (NCI)·Phase 2·NCT05185947·21 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)